Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 in Progressive Metastatic Castration-Resistant Prostate Cancer
NCT03042468Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Primary endpoints: Dose Limiting Toxicity at 92 days, Maximum Tolerated Dose at 92 days and 1 more. Started Dec 2016; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03042468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042468.